Urinary Tract Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Urinary Tract Infection Testing Market is projected to expand from USD 636.57 Million in 2025 to USD 815.27 Million by 2031, reflecting a compound annual growth rate of 4.21%. This sector includes various diagnostic techniques such as urinalysis, urine culture, and molecular diagnostics intended to identify pathogens within the urinary tract.

Growth is largely driven by the increasing global incidence of urinary tract infections, especially among women and the elderly, as well as a rise in hospital-acquired cases like those associated with catheters. Additionally, the adoption of testing solutions is being hastened by the urgent need for rapid point-of-care options that enable immediate treatment. As noted by the American Urological Association in 2024, an estimated 150 million urinary tract infections occur annually worldwide, resulting in healthcare costs totaling 6 billion dollars.

Despite these positive growth metrics, the market encounters a substantial obstacle regarding the diagnostic precision of traditional rapid screening tools. Conventional urine dipstick tests frequently demonstrate insufficient sensitivity and specificity, causing high instances of false negatives or positives that may lead to untreated conditions or unwarranted antibiotic usage. Consequently, this limitation forces a dependence on slower urine cultures for verification, delaying appropriate therapy and potentially impeding the broader uptake of rapid diagnostic methods in cost-conscious medical environments.

Market Drivers

The rising global prevalence of urinary tract infections serves as a major market propellant, creating a need for high-volume diagnostic capacities in medical facilities. This demand is further amplified by the escalating issue of antimicrobial resistance (AMR), which makes empirical treatment difficult and necessitates exact pathogen detection to avoid complications like urosepsis or pyelonephritis. As standard antibiotics lose efficacy against resistant strains, clinical reliance on accurate screening and culture confirmation has grown. According to an October 2024 announcement by the U.S. Food and Drug Administration regarding new treatments for uncomplicated infections, roughly half of all women will suffer at least one such infection during their lives, ensuring a steady and increasing demand for diagnostic services to handle acute and recurrent cases.

Concurrently, the surge in point-of-care testing technologies is revolutionizing the sector by fulfilling the urgent requirement for speed and diagnostic accuracy. Medical providers are progressively moving away from traditional techniques that take days to yield results, opting instead for molecular and rapid phenotypic tests that facilitate instant clinical decisions. This shift is highlighted by the Centers for Disease Control and Prevention’s November 2024 update on antibiotic use, which noted a greater than 50-fold increase in Medicare claims for multiplex molecular urinary tract infection tests between 2016 and 2023. Additionally, innovations in rapid susceptibility testing are speeding up this transition; for instance, bioMérieux reported in 2024 that the VITEK REVEAL AST System can provide actionable data for specific gram-negative bacteria within an average of 5.5 to 6 hours, greatly improving the timeline for targeted treatments.

Market Challenges

The principal obstacle restricting the Global Urinary Tract Infection Testing Market is the inadequate diagnostic accuracy found in standard rapid screening techniques. Although urine dipstick tests are commonly used due to their affordability and speed, they often lack the sensitivity and specificity needed for conclusive medical diagnoses. This technical deficiency compels healthcare practitioners to rely on slow urine cultures to confirm findings, essentially canceling out the immediacy intended by point-of-care solutions. As a result, the market faces difficulties in fully shifting towards decentralized testing models, as clinicians are unable to trust treatment decisions exclusively to rapid diagnostics that are susceptible to errors.

This absence of precision leads to considerable operational inefficiencies and clinical dangers that inhibit market growth. High occurrences of false-positive results frequently cause unnecessary antibiotic prescriptions, whereas false negatives delay treatment for patients in need of urgent attention. The magnitude of this diagnostic shortcoming is highlighted by recent data; the American Urological Association reported in 2025 that standard urinalysis markers, such as positive leukocyte esterase and nitrites, demonstrated positive predictive values of less than 50% for detecting actual infections. Such statistics demonstrate that current rapid tools frequently fail to differentiate between genuine infection and contamination, forcing healthcare systems to sustain costly, labor-intensive reference laboratory processes that reduce overall market throughput.

Market Trends

The proliferation of home-based and self-testing environments is significantly transforming the Global Urinary Tract Infection Testing Market by decentralizing care access and reducing the pressure on primary medical facilities. This movement is defined by the growing accessibility of direct-to-consumer diagnostic kits and pharmacy-managed testing services, enabling patients to receive rapid screening and immediate therapy without visiting a general practitioner. This transition is especially apparent in areas adopting policies that empower community pharmacists, establishing a new, high-volume growth channel beyond traditional hospitals. As reported by The Pharmacist in April 2025 regarding the first year of Pharmacy First consultations, 607,646 consultations for uncomplicated urinary tract infections were conducted via the service in England between February 2024 and January 2025, underscoring substantial consumer uptake of decentralized testing routes.

At the same time, the market is undergoing a notable pivot toward molecular and genomic diagnostic techniques, motivated by the necessity to surpass the performance constraints of standard microbiological methods. While traditional practices remain prevalent, their failure to detect fastidious organisms or supply rapid antimicrobial susceptibility data has hastened the adoption of next-generation sequencing (NGS) and advanced genomic platforms in routine diagnostics. These advanced technologies provide enhanced sensitivity and specificity, allowing for the accurate identification of pathogens often missed by conventional cultures, thereby reducing the risks of ineffective antibiotic use and recurrent infections. According to a September 2025 announcement by Biotia regarding their advanced test offering, standard urine cultures fail approximately 30% of the time, a diagnostic deficiency that is actively driving the clinical shift toward more dependable genomic-based testing solutions.

Key Players Profiled in the Urinary Tract Infection Testing Market

• QIAGEN NV
• Accelerate Diagnostics, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Siemens Healthcare GmbH
• Randox Laboratories Ltd.
• Thermo Fisher Scientific, Inc.
• BIOMeRIEUX
• T2 Biosystems, Inc.

Report Scope

In this report, the Global Urinary Tract Infection Testing Market has been segmented into the following categories:

Urinary Tract Infection Testing Market, by Type:

• Urethritis
• Cystitis
• Pyelonephritis

Urinary Tract Infection Testing Market, by End use:

• General Practitioners (GPs)
• Urologists
• Urogynecologists
• Hospital Laboratories
• Reference Laboratories
• Others

Urinary Tract Infection Testing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Urinary Tract Infection Testing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.